Amgen teams up with BeiGene to expand its oncology presence in China
Category: #health  By Nikita Chaurasia  Date: 2019-11-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Amgen teams up with BeiGene to expand its oncology presence in China

The pharmaceutical sector is often held accountable for treating the most crucial health conditions. The sector markets, innovates and produces those therapies which could become beneficial to patients on a larger scale. However, with increasing competition, pharma companies are obligated to plan ahead, developing new ways to increase their market presence.

Amgen Inc., a U.S.-based biopharmaceutical company, has recently made one such stride when it announced that it has signed a strategic partnership with BeiGene to accelerate its intention to spread Amgen’s oncology presence into China.

For the record, BeiGene is an oncology-focused, research-based biotech firm that owns a highly experienced and established team in China, including a 600-person clinical development organization and a 700-person commercial organization.

Sources cite that the collaboration will see Amgen buy a 20.5% stake in BeiGene for nearly $2.7 billion in cash. Amgen would also choose one of its members to serve on the Board of Directors of BeiGene.

Meanwhile, under the agreement, BeiGene would commercialize KYPROLIS® (carfilzomib), BLINCYTO® (blinatumomab) and XGEVA® (denosumab) in China and both the parties share profits and losses equally. However, two of these items would be reverted back to Amgen, one after seven years and the other after five.

According to Robert A. Bradway, Chairman and Chief Executive Officer, Amgen, this partnership with BeiGene would allow their company to significantly reach more patients by growing its presence in one of the most populous nations. Bradway claims that cancer is the foremost cause of death in the country and will grow to become a severe public health problem as Chinese inhabitants get aged.

He further added that, with BeiGene’s extensive clinical and commercial abilities within China along with a determined mindset towards global quality standards, it would be the most ideal collaborator for their company as it strives to make an impacting difference in millions of cancer patients’ lives in China as well as across the globe.
 

Source Credit: https://www.amgen.com/media/news-releases/2019/10/amgen-enters-into-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Amazon adds indoor surveillance drone to security solutions portfolio
Amazon adds indoor surveillance drone to security solutions portfolio
By Nikita Chaurasia

  This is the next big launch after the announcement of car security devices Indoor drone will offer video surveillance in places devoid of static cameras U.S.-based multinational technology giant, Amazon.com Inc. along with Ring Inc. has ...

JPMorgan to move USD 234 billion worth assets to Germany before Brexit
JPMorgan to move USD 234 billion worth assets to Germany before Brexit
By Nikita Chaurasia

  JPMorgan indicated plans to expand its hub in Paris by reassigning services based in London post Brexit The bank plans on completing the migration of its assets to the Frankfurt subsidiary by the end of 2020 As per reliable sources, Amer...

Nike plans to exit brick & mortar stores, records mega returns online
Nike plans to exit brick & mortar stores, records mega returns online
By Nikita Chaurasia

U.S.-based multinational sports apparel firm, Nike Inc., has reportedly revealed a significant upturn in their digital sales amid the COVID-19 pandemic, recording a revenue of USD 10.6 billion. Sources close to the matter claim that the company plans...